Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

Submit a Proposal  Contact Us

New Manuscript Highlights ARLG Achievements and 2.0 Scientific Agenda

Health organizations such as the Centers for Disease Control (CDC) and the National Institute of Allergy and Infectious Diseases (NIAID) continue to sound the alarm over the ongoing global threat of antibacterial resistance. A new manuscript published in Clinical Infectious Diseases details how renewed funding of more than $100 million from the NIAID enables a network of more than 100 infectious diseases experts with the Antibacterial Resistance Leadership Group (ARLG) to prioritize, design, and execute innovative clinical research to combat antibacterial resistance.

The manuscript, "Antibacterial Resistance Leadership 2.0 – Back to Business", updates the scientific community on the accomplishments facilitated by ARLG’s initial 2013 grant and outlines how the research agenda for the seven-year, competitive renewal awarded in December 2019 is addressing the antibacterial resistance crisis.

The Duke Clinical Research Institute serves as the operational coordinating center for the ARLG network, which has initiated more than 55 studies in 19 countries, and has published more than 155 manuscripts. The updated agenda prioritizes the execution of clinical research that combines ARLG’s international networks, innovative study design, and strong operational structure while highlighting core values such as mentoring and
ARLG Spotlight: Michael Satlin

About my role in the ARLG

As an ARLG trialist in training, I receive funding, guidance, and mentorship that is allowing me to lead a multicenter study to identify the frequency and clinical significance of colonization with fluoroquinolone-resistant gut bacteria in neutropenic patients. In addition, ARLG has given me the opportunity to participate on the Gram-Negative Subcommittee and Immunocompromised Host Working Group where I can contribute to the development of other clinical trials.

About my research

Patients with hematologic malignancies are uniquely susceptible to life-threatening bloodstream infections from gram-negative gut bacteria when they are neutropenic after chemotherapy. The current standard-of-care is to administer fluoroquinolones prophylactically to prevent gram-negative infections during neutropenia. However, the rising rate of bacterial resistance to fluoroquinolone threatens the effectiveness of this approach.

Our study will determine the frequency of colonization with fluoroquinolone-resistant Enterobacterales in this patient population when they begin chemotherapy. We will also assess whether patients colonized with these bacteria are more likely to develop gram-negative bloodstream infections.

Impact of ARLG mentoring and funding on my career

I am forever grateful that ARLG’s mentorship and opportunities have allowed me to successfully launch my research career. Senior ARLG members helped to provide the preliminary data for the current study by serving on a Scientific Advisory Board to support my K23 Career Development Award. The mentorship guided my transition from the initial award all the way to becoming an independent investigator. The opportunity to network with leading clinical researchers in the field of antimicrobial resistance has also led to additional collaborative research and grant funding.
News

Thomas Holland Chosen as Presidential Award Team Winner

ARLG primary investigator, Thomas L. Holland, MD, is being honored alongside Cameron R. Wolfe, MBBS, and the Division of Infectious Diseases, all with Duke University Hospital, to receive the Presidential Award.

Holland, Wolfe, and members of their team were nominated for the award in recognition of their leadership and service efforts to combat the COVID-19 pandemic.

Tori Kinamon Awarded FDA ORISE Fellowship!

The Food and Drug Association (FDA) selected Air Force 2nd Lt. Tori Kinamon, MD Candidate at the Duke University School of Medicine, to receive an FDA Antibacterial Drug Resistance (DOOR) Fellowship, which evaluates ordinal endpoints using the Desirability of Outcome Ranking (DOOR) approach for anti-infective clinical trials. The one year fellowship, which begins June 2021, is with the Office of Infectious Diseases Division of Anti-infectives led by Sumanthi Nambiar, MD.
ARLG Early Stage Investigator
Seed Grant Opportunities

As part of our mission to mentor the next generation of researchers and foster diversity, ARLG offers seed grant opportunities to help early stage investigators (ESI) develop preliminary data and apply for additional external funding.

**ESI Seed Grants** offer up to $50,000 in direct costs for research in any area related to antibacterial resistance for up to five ESIs.

**Early Stage Investigator Program Promoting Diversity in Antibiotic Resistance Research (EVERYONE) Seed Grants** aim to foster diversity in the field of antibacterial resistance by offering up to $50,000 in direct costs for research in any area related to antibacterial resistance for up to two EVERYONE investigators.

Individuals who are MD, PhD, or Pharm D students, graduate or post-graduate trainees, or those with a faculty appointment of less than five years are all eligible to apply.

Events and Deadlines

Join ARLG Members at SHEA Spring 2021!

Be on the lookout for ARLG members at the Society for Healthcare Epidemiology of America (SHEA) Spring 2021 Conference which takes place from April 13-16. SHEA Spring 2021 features networking and mentorship opportunities, valuable workshops, abstract sessions, and conference sessions focused on a variety of infections and antibiotic resistance related topics. Though the event is virtual this year, SHEA Spring 2021 continues to connect participants with one another to learn and advance the fields of healthcare epidemiology and antibiotic stewardship.
The American Society for Microbiology (ASM) and the Federation for European Microbiological Societies (FEMS) have teamed up to bring you the World Microbe Forum happening online June 20 – 24.

Experts from around the world will offer insight and discuss solutions on topics such as infectious pathogens, agriculture and food microbiology, and the role of microbes in climate change.

Abstract submission reopens April 23 and closes May 7!

Learn more about the submission guidelines and how to register for the event.

---

ECCMID 2021 Late-breaking Abstract Deadline

The European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) is coming up soon! From July 9 – 12, clinical microbiology and international infectious diseases experts will present their latest findings and information.

The event will take place in Vienna, Austria and online. There is still time to share your research or case report.

Late-breaking abstracts will be accepted April 26 - May 7, 2021.

Get more information about the guidelines and register for the event.
Connect at IDWeek 2021

Stay tuned! IDWeek 2021 will be here before you know it. This year’s event will happen September 29-October 3, 2021 and will offer access to networking and collaborative opportunities with ARLG thought leaders and other experts in infectious diseases. The annual meeting will give participants a chance to learn from one another, while working to improve public health and patient care.

Abstract submissions will be accepted until June 9, 2021.

Learn more

Study Milestones

View recent ARLG study updates.

<table>
<thead>
<tr>
<th>Study</th>
<th>Milestone Description</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMBINE</td>
<td>AVYCAZ® in COMBINATION with Aztreonam</td>
<td>Database locked</td>
</tr>
<tr>
<td>DOTS</td>
<td>Dalbavancin as an Option for Treatment of S. aureus Bacteremia</td>
<td>Enrolling</td>
</tr>
<tr>
<td>SCENE</td>
<td>Screening for Colonization with Resistant Enterobacteriales in Neutropenic Patients with Hematologic Malignancies</td>
<td>Enrolling (FPI)</td>
</tr>
<tr>
<td>MDRO: SHREC</td>
<td>MDRO: Study of Highly Resistant Escherichia coli</td>
<td>Enrollment 98% complete</td>
</tr>
</tbody>
</table>

Go to the ARLG Studies page for more milestones and updates!
Recent Publications

View the following recent ARLG publications.


